Kawin Biosciences

Kawin Biosciences, officially known as Beijing Kawin Technology Share-Holding Co., Ltd., is a prominent Chinese biopharmaceutical company focused on the development and commercialization of therapies for viral hepatitis and other liver-related diseases. The company achieved significant recognition by launching Yapeigeng, the first domestically developed pegylated interferon alpha-2b in China, which serves as a cornerstone treatment for chronic Hepatitis B and C. Beyond its interferon portfolio, Kawin has expanded into small molecule direct-acting antivirals, such as Kobuvir, and is advancing a pipeline of monoclonal antibodies and long-acting recombinant proteins. Headquartered in Beijing, the company operates integrated research, development, and GMP-certified manufacturing facilities. Kawin is publicly traded on the Shanghai Stock Exchange's STAR Market and continues to strengthen its position in the infectious disease and immunology sectors.